Clinical Trial Update: MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube, and primary peritoneal cancer (MITO 35a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN